Clinical Trial Update: Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Pfizer is conducting a Phase 2 study to evaluate the safety and efficacy of PF-06835375 in primary immune thrombocytopenia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• PF-06835375

Snippet

Sponsor: Pfizer | Conditions: Primary Immune Thrombocytopenia | Phase 2 | Status: RECRUITING